GeneDx Holdings WGS Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares at other companies

WSFS FinancialWSFS

0-100%

Flagstar Bank FLG

5.7M-39.3%

WaFd, Inc.WAFD

827.8K-1.8%

MSCIMSCI

577K+63.9%

SBA CommunicationsSBAC

14K-30.0%

Tarsus Pharmaceuticals, Inc.TARS

1.5M-13.8%

Other financials

Income statement

See full

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

See full

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

See full

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

See full

Market cap$1.89B-24.3%

Enterprise value$1.89B-22.8%

P/S4.3×-3.3×

Profitability

See full

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's sharebased compensation arrangement by sharebased payment award options nonvested number of shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GeneDx Holdings's sharebased compensation arrangement by sharebased payment award options nonvested number of shares?: GeneDx Holdings (WGS) reported sharebased compensation arrangement by sharebased payment award options nonvested number of shares of 1.5K in Q1 2026.